NCT04234568View on ClinicalTrials.gov

Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

July 20, 2020

Primary Completion Date

September 17, 2024

Study Completion Date

March 14, 2026

Conditions
Metastatic Digestive System Neuroendocrine NeoplasmMetastatic Neuroendocrine Tumor
Interventions
PROCEDURE

Biospecimen Collection

Correlative studies

PROCEDURE

Computed Tomography

Undergo CT

DRUG

Lutetium Lu 177 Dotatate

Given IV

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

DRUG

Triapine

Given PO

Trial Locations (11)

15232

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

33612

Moffitt Cancer Center, Tampa

40536

University of Kentucky/Markey Cancer Center, Lexington

43210

Ohio State University Comprehensive Cancer Center, Columbus

55905

Mayo Clinic in Rochester, Rochester

60611

Northwestern University, Chicago

84112

Huntsman Cancer Institute/University of Utah, Salt Lake City

85054

Mayo Clinic Hospital in Arizona, Phoenix

91010

City of Hope Comprehensive Cancer Center, Duarte

32224-9980

Mayo Clinic in Florida, Jacksonville

02215

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH